Savas Comlek

Savas Comlek

Auto-generated profile, based on publicly available information

Savas Comlek

Department of Anesthesiology and Reanimation, Gayrettepe Florence Nightingale Hospital, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
SCSavas Comlek
Savas Comlek
Background/Aims: In most instances of abdominal pain associated with pancreatic cancer, pain may become refractory to increasing doses of narcotics. Celiac plexus neurolysis represents an option; however, altered celiac plexus anatomy may render this treatment infeasible or ineffective, where splanchnic nerve neurolysis may represent another option. This study aimed to investigate the outcomes of splanchnic neurolysis in pancreatic cancer patients not responsive to celiac plexus neurolysis. Patients and Methods: Among all 84 patients who underwent celiac plexus neurolysis for pancreatic cancer pain during the study period, 34 patients did not respond and underwent splanchnic nerve neurolysis under fluoroscopic guidance and thus included in this retrospective study. Stage IV, III, and II disease was present in 38.2%, 47.1%, and 14.7% of the patients. During the study, 88.2% were receiving chemotherapy, whereas none were on radiotherapy. Data for daily narcotic dose equivalents and Visual Analogue Scale (VAS) scores during outpatient visits at baseline, 2 weeks, 2 months, and 3 months were extracted. Results: Pain response rates were 76.5%, 84.4%, and 71.0%, at 2 weeks, 2 months, and 3 months, respectively. A significant and dramatic reduction was seen in VAS scores at 2 weeks (2.8± 1.2 versus 6.3± 1.1, p< 0.001), and this significant decline was maintained for 3 months. Similarly, a significant and dramatic reduction was seen in daily narcotic need at 2 weeks (20.8± 32.9 versus 93.4± 86.2 mg, p< 0.001), which was also maintained during the 3-month follow-up. The procedure was generally well tolerated. Conclusion: Findings of this study suggest that splanchnic neurolysis represents a durable and effective option for pain control in pancreatic cancer patients in whom the neurolysis of the celiac plexus is ineffective. However, these conclusions refer to only preliminary single-center results in a selected patient group; thus, further large studies are warranted.


24 June 2024 in Medical Science Monitor
Verified
Journal Article
Open access
SCSavas Comlek
Savas Comlek
Dilek BaykalDilek Baykal
Dilek Baykal
LOLevent Ozgonenel
Levent Ozgonenel
Knee osteoarthritis (OA) is a chronic disease caused by cartilage degeneration in the joint accompanied by joint deformities, pain, and stiffness. This study assessed the changes over time in the Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) and Visual Analog Scale (VAS) values of patients after the combined application of stromal vascular fraction (SVF) and platelet-rich plasma (PRP). A retrospective clinical study was designed. Thirty-four patients (8 males, 26 females, mean age 65.21±10.71, range 30–83 years) with pain due to knee osteoarthritis received SVF and PRP between 2019 and 2020. During and after the procedure, ultrasound-guided intra-articular spread was checked. PRP+SVF injection provided significant improvement in the clinical symptoms of the patients measured according to their VAS and WOMAC scores, and this improvement continued until the twelfth month. The change in VAS scores of the patients was 1.76±1.18 (P=0.000) in the first month, 1.50±1.46 (P=0.000) in the sixth month, and 1.53±1.41 (P=0.000) in the twelfth month. VAS scores decreased 6.6 to 1.6 point at the end of the twelfth month. The WOMAC scores of the patients were 23.20±12.12 (P=0.000) in the first month, 19.48±12.0 (P=0.000) in the sixth month, and 20.01±10.48 (P=0.000) in the twelfth month. WOMAC scores decreased 51.99 to 20.48 point at the end of the twelfth month. Applying ultrasound-guided PRP+SVF injection into the knee joint once in OA patients improved VAS and WOMAC scores.

1 September 2021 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
SCSavas Comlek
Savas Comlek
Sezer SaglamSezer Saglam
Sezer Saglam
Background: Intrathecal chemotherapy is a local therapeutic modality used for treatment of leptomeningeal metastases. However, the techniques currently used, i.e. repeated lumbar puncture and Ommaya reservoir, have certain disadvantages. Lumbar intrathecal port (LIP) placement is a relatively novel technique, which has been used for pain management in cancer patients. Objective: To investigate the use of LIP for intrathecal administration of chemotherapeutic agents in patients with leptomeningeal metastases. Methods: Retrospective study of 13 patients treated with intrathecal chemotherapy for secondary leptomeningeal involvement of a primary solid tumor were included in this retrospective study. The patients received intrathecal chemotherapy through a LIP. Results: The patients received a total of 123 intrathecal chemotherapy doses. No grade 3-4 toxicity, technical problem or severe complication developed. During a median of 136 days of follow-up (range, 67-376 days), 12 patients died (92.3%). The treatment resulted in symptom improvement in all patients and self-rated overall health and quality of life improved, compared with baseline. Conclusions: The LIP system, which has been used for intrathecal pain management for decades, appears to offer a safe alternative for intrathecal chemotherapy in patients with leptomeningeal metastases. Further studies are warranted to clarify its potential use in this setting.

19 February 2020 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
SCSavas Comlek
Savas Comlek
Introduction: Development of hypersensitivity pneumonitis has been reported in association with combination chemotherapy consisting of gemcitabine and paclitaxel. However, diagnosis of this condition is based on computed tomography imaging and correlative bronchoalveolar findings on bronchoscopy. Although transient elevation of the tumor marker CA 15-3 has been reported in patients with interstitial pneumonitis associated with collagen disease, elevation of this marker during drug-induced hypersensitivity pneumonitis has not been reported yet. Case report: In this report, we describe a 74-year-old metastatic schwannoma patient with drug-induced pneumonitis secondary to combined gemcitabine and paclitaxel treatment associated with transient elevation of CA 15-3. Management and outcome: The patient responded to steroid treatment with clinical and radiological improvement, and CA 15-3 levels returned to normal within four weeks. Discussion: These findings suggest that blood CA 15-3 level has the potential to be used as a marker to monitor drug-induced pneumonitis.